Nerandomilast in Systemic Autoimmune Rheumatic Disease–Associated Interstitial Lung Disease

Phase 3, randomised, double-blind trial in connective tissue disease-associated interstitial lung disease (CTD-ILD), systemic sclerosis (SSc), rheumatoid arthritis (RA) and 3 more comparing Nerandomilast (BI 1015550) with Placebo (2 arms). Primary endpoint: Absolute change from baseline in QILD score [%] on HRCT at Week 26. Planned start Nov 2025; status: authorised.